|
|
About the drug Priligy |
Nearly 30 percent of males across the world are affected with the
condition known as Premature Ejaculation – PE and in spite of such a
remarkable shocking percentage there are hardly any effective
medications designed for treating this condition. However, one drug
is of course in the research phase now and the researchers are well
working with Johnson & Johnson for developing their branded
medication Priligy using Dapoxetine Hydrochloride as its active
pharmaceutical ingredient.
Though this very product has been issued the ‘Non-approvable’ letter
by the FDA during October 2005, the company is highly hopeful of
getting the formal approval. The DFA has anyway indicated that
further research is required for addressing the questions with the
medication before it is awarded the final approval.
The innovative medication Priligy – Dapoxetine belongs to the
category of Selective Serotonin Reuptake Inhibitor – SSRIs with a
short half-life of merely 1 or 2 hours. It helps getting the apex
plasma levels within one hour so in short the drug effect gets in
faster and gets out faster as well. The short half-life means that
the males could probably take this medication when required instead
of relatively building up the typical level in the body like that of
the traditional SSRIs due to the short half-life it does not gather
in the system and source other side effects like loss of libido.
There are further lines of study for Priligy – Dapoxetine
Hydrochloride that may incorporate considering various dose
strengths of this medication for fluctuating levels of ejaculation
latency time – ELT.
|
|
